EBR October 2020 |
In order for CRISPR gene editing to reach its full potential, we must develop in vitro delivery approaches that will allow us to work with hard-to-transfect cells, large repair templates, multiplex editing projects, and minimise off-target effects.
By Dr. Paul Monnier, Field Application Scientist, Cytosurge
This article is taken from European Biopharmaceutical Review October 2020, pages 34-37.
© Samedan Ltd.